Home » Topics » BioWorld Science

BioWorld Science
RSS

Selinexor shows antiviral and the anti-inflammatory effects in models of SARS-CoV-2 infection

July 29, 2021

Phase II study of CETP inhibitor obicetrapib meets primary endpoint

July 29, 2021

MMV-688533 shows excellent single-dose efficacy in P. falciparum-infected mouse model

July 29, 2021

ISIS-814907 well tolerated in first-in-human study in mild Alzheimer's disease patients

July 29, 2021

New serine-protein kinase ATM inhibitors described by Medshine Discovery

July 29, 2021

Vonafexor meets primary endpoint in the phase IIa LIVIFY study in patients with NASH

July 29, 2021

FDA authorizes phase II study of autologous adipose-derived mesenchymal stem cells in MS

July 29, 2021

First patients dosed in new studies of Xpovio in melanoma and myelofibrosis

July 29, 2021

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent PD-1/PD-L1 inhibitors

July 29, 2021

New RORgammaT agonists identified at Sunshine Lake Pharma

July 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...